Pancreatic cancer is likely to become the second most frequent cause of cancer-associated
mortality within the next decade. Surgical resection with adjuvant systemic chemotherapy …

Pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis, with a median survival
time of 10-12 months. Clinically, these poor outcomes are attributed to several factors …

PURPOSE The benefit of neoadjuvant chemoradiotherapy in resectable and borderline
resectable pancreatic cancer remains controversial. Initial results of the PREOPANC trial …

PURPOSE Preoperative chemoradiotherapy may improve the radical resection rate for
resectable or borderline resectable pancreatic cancer, but the overall benefit is unproven …

Evidence-based guidelines on the management of pancreatic cystic neoplasms (PCN) are
lacking. This guideline is a joint initiative of the European Study Group on Cystic Tumours of …

A recent study estimating cancer epidemiology in 2014 (within Europe) showed that
pancreatic cancer was the fourth most fatal cancer in men after lung, colorectal, and prostate …

Pancreatic cancer is one of the most lethal solid organ tumors. Due to the rising incidence,
late diagnosis, and limited treatment options, it is expected to be the second leading cause …

The opportunity to detect pancreatic cancer (PC) when potentially curable depends on early
diagnosis and an ability to identify and screen high-risk populations before symptoms arise …

Pancreatic cancer is one of the solid tumors with the worst prognosis. Five-year survival rate
is less than 10%. Surgical resection is the only potentially curative treatment, but the tumor is …

Objective: The aim of this study was to evaluate and validate the proposed 8th edition
American Joint Committee on Cancer (AJCC) system for T and N staging of pancreatic …